(Q35622736)

9 August 2017

1 reference

title

Current immunosuppressive agents: efficacy, side effects, and utilization (English)

1 reference

9 August 2017

Jodi M Smith

1

1 reference

9 August 2017

Thomas Lajos Nemeth

series ordinal

2

1 reference

9 August 2017

Ruth A McDonald

series ordinal

3

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Pediatric Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

50

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

1283-1300

1 reference

Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Antibody therapy as an induction regimen in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

A generic cyclosporine development program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Current opinions on therapeutic drug monitoring of immunosuppressive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Neoral absorption profiling: an evolution in effectiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Pharmacokinetic validation of neoral absorption profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Pediatric renal transplantation under FK-506 immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

FK506 in pediatric kidney transplantation--primary and rescue experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Sirolimus: continuing the evolution of transplant immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Grapefruit juice activates P-glycoprotein-mediated drug transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Mycophenolate mofetil in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Mycophenolate mofetil--is it worth the cost? The in-favor opinion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

What is the role for mycophenolate mofetil in pediatric renal transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

The potential role of rapamycin in pediatric transplantation as observed from adult studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

The role of Certican (everolimus, rad) in the many pathways of chronic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

The role of T-cell costimulatory activation pathways in transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

CD40 and its ligand in host defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

Long-term kidney transplant survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Evolution of immunosuppression and continued importance of acute rejection in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Maintenance immunosuppression in the renal transplant recipient: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900121-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0031-3955(03)00121-4

1 reference

9 August 2017

1 reference